Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
49 studies found for:    Open Studies | "Cytomegalovirus Infections"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Cytomegalovirus Infections"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Donor Lymphocyte Infusion for Treatment of CMV Infection
Conditions: Stem Cell Transplantation, Hematopoietic;   CMV Infection;   Hematological Diseases
Interventions: Biological: DLI;   Biological: MSCs
2 Unknown  Comparison of Two Immunosuppressive Regimens in Kidney Transplant Recipients With Deceased Donors With the Aim of Preventing the Development of Fibrosis / Atrophy of Reducing the Incidence of Cytomegalovirus Infection
Conditions: Disorder of Transplanted Kidney;   Cytomegalovirus Infections
Intervention:
3 Recruiting Evaluation of the PK and PD of Ganciclovir in Premature Infants Receiving Treatment for CMV Infection
Condition: Cytomegalovirus Infections
Intervention:
4 Recruiting A Study of RG7667 for the Prevention of Cytomegalovirus Disease in Kidney Transplant Recipients
Condition: Cytomegalovirus Infections
Interventions: Drug: RG7667;   Drug: Placebo
5 Recruiting A French Cohort of Transplant Recipients With CMV Infection : Risk Factors for Antiviral Resistance in the Prophylaxis Era.
Condition: Transplant Recipients With CMV Infection
Intervention: Biological: CMV Infection
6 Recruiting Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
Conditions: CMV Infection;   Persistent CMV Viremia
Intervention: Genetic: CMVpp65 Specific T-cells
7 Unknown  Certican® (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients
Condition: Cytomegalovirus Disease
Interventions: Drug: Certican (everolimus) + valganciclovir;   Drug: Valganciclovir
8 Not yet recruiting Diagnosis of Congenital CMV Infection in Neonates Who Failed Newborn Hearing Screening
Condition: Congenital Cytomegalovirus Infection
Intervention: Other: CMV PCR
9 Recruiting Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Promyelocytic Leukemia (M3);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma;   Anaplastic Large Cell Lymphoma;   B-cell Adult Acute Lymphoblastic Leukemia;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cytomegalovirus Infection;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Extramedullary Plasmacytoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Isolated Plasmacytoma of Bone;   Monoclonal Gammopathy of Undetermined Significance;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Central Nervous System Hodgkin Lymphoma;   Primary Central Nervous System Non-Hodgkin Lymphoma;   Primary Myelofibrosis;   Progressive Hairy Cell Leukemia, Initial Treatment;   Prolymphocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Multiple Myeloma;   Stage I Small Lymphocytic Lymphoma;   Stage IA Mycosis Fungoides/Sezary Syndrome;   Stage IB Mycosis Fungoides/Sezary Syndrome;   Stage II Adult Hodgkin Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage IIA Mycosis Fungoides/Sezary Syndrome;   Stage IIB Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Multiple Myeloma;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
Interventions: Biological: tetanus-CMV fusion peptide vaccine;   Other: laboratory biomarker analysis
10 Not yet recruiting Immunological Characteristics of Maternal-fetal Transmission of Cytomegalovirus in Pregnancy
Conditions: Pregnancy;   Cytomegalovirus Infections;   Congenital Infection
Intervention:
11 Recruiting A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)
Conditions: Congenital Cytomegalovirus Infection;   Maternal Cytomegalovirus Infection
Intervention: Drug: CMV hyperimmune globulin
12 Unknown  Prevention of Transplant Atherosclerosis With Everolimus and Anti-cytomegalovirus Therapy
Conditions: Heart Transplantation;   Cardiac Allograft Vasculopathy;   Cytomegalovirus Infection
Interventions: Drug: Pre-emptive strategy with valganciclovir plus everolimus;   Drug: Prophylaxis with valganciclovir plus mycophenolate;   Drug: Prophylaxis with valganciclovir plus everolimus;   Drug: Pre-emptive mycophenolate
13 Not yet recruiting Evaluation of Early Use of Everolimus (EVE) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients
Condition: Cytomegalovirus Infections
Interventions: Drug: Everolimus+Tacrolimus+Prednisone;   Drug: Mycophenolate+Tacrolimus+Prednisone
14 Recruiting Clinical Trial of Behavioral Modification to Prevent Congenital Cytomegalovirus
Conditions: Cytomegalovirus Infections;   Pregnancy;   Behavior
Intervention: Behavioral: Educational Intervention
15 Unknown  Genotyping of Cytomegalovirus From Patients in Israel
Condition: Cytomegalovirus Infections
Intervention:
16 Unknown  Evaluation of the Safety and Efficacy of Standard Intravenous Immunoglobulins in Pregnant Women With Primary Cytomegalovirus Infection
Condition: Cytomegalovirus Congenital Infection
Intervention: Biological: standard intravenous immunoglobulin
17 Recruiting Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts
Conditions: Sensorineural Hearing Loss;   Cytomegalovirus Infection
Intervention:
18 Recruiting An Evaluation of a Cytomegalovirus (CMV) Vaccine (ASP0113) in CMV-Seropositive and CMV-Seronegative Healthy Subjects and CMV-Seronegative Dialysis Patients
Conditions: Healthy Subjects;   Cytomegalovirus Infection;   Dialysis
Interventions: Drug: ASP0113;   Drug: Placebo
19 Recruiting Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Allo-HSCT Recipients
Conditions: Cytomegalovirus Infection;   GVHD
Intervention:
20 Recruiting Vaccine Therapy in Healthy Volunteers With or Without Previous Exposure to Cytomegalovirus
Conditions: Cytomegalovirus Infection;   Healthy, no Evidence of Disease
Interventions: Biological: multi-CMV epitope modified vaccinia Ankara vaccine;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years